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. In conclusion, in the conscious dog, the direct effects of NE and EPI on HGP are predominantly mediated through ␣ 1 -and ␤ 2 -adrenergic receptors, respectively. adrenergic receptor; hepatic glucose production; glycogenolytic rate IN STRESSFUL CONDITIONS and pathophysiological states (e.g., exercise, hypoglycemia, and shock), the rise in circulating catecholamines plays an important role in stimulating liver glucose output (2, 5, 7, 21, 22, 26) .
The stimulatory effects of the catecholamines on hepatic glucose production arise from their actions on extrahepatic tissues (muscle and adipose tissue) and on the liver. Previous studies in humans (21, 22) and other animals (7, 26) have shown that plasma catecholamines can stimulate glycogenolysis in muscle and lipolysis in adipose tissue and thereby move lactate, alanine, glycerol, and free fatty acids (FFA) to the liver. This in turn increases hepatic gluconeogenesis. Our recent studies (2, 3, 5) have shown that the direct hepatic effects of the catecholamines [norepinephrine (NE) and epinephrine (EPI)] are attributable to their stimulation of glycogenolysis. Taken together, the above studies have shown that the direct and indirect effects of the catecholamines on the liver relate to their glycogenolytic and gluconeogenic actions, respectively. Furthermore, in vitro work (10, 25, 27) has suggested that EPI works on the liver primarily via ␤-receptors, whereas NE works through ␣-receptors.
Recent studies in dog hepatocytes (14, 15) showed that the distribution of adrenergic receptors in canine liver is similar to the distribution in human liver (13) , that is, predominantly the ␣ 1 -and ␤ 2 -subtypes. Because the intracellular signaling pathways of ␣ 1 -and ␤ 2 -adrenergic receptor subtypes are mediated through the G protein isoform Gq as well as Ca 2ϩ , and the isoform Gs as well as cAMP, respectively (10, 27) , it becomes of interest to determine whether EPI and NE bring about the same hepatic action (glycogenolysis) in the dog through different adrenergic mechanisms. This is all the more important in light of our recent finding (5) that the patterns of the stimulatory effects of the two catecholamines on hepatic glycogenolysis are quite different. The direct effect of EPI is similar to that of glucagon, in that it is quick but wanes with time. The action of NE, although on a molar basis less potent than that of EPI, is sustained over time.
The aim of the present study, therefore, was to determine whether EPI and NE exert their action on glucose production through different hepatic adrenergic receptor subtypes in the conscious dog. To focus on their hepatic actions, the catecholamines were infused portally to avoid their effects on muscle and adipose tissue, and a pancreatic clamp was used to eliminate their effects on the pancreas. Similarly, the adrenergic blockers were infused portally to avoid their effects on the cardiovascular system.
METHODS AND MATERIALS
Experiments were carried out on sixteen 18-h-fasted conscious mongrel dogs (20-30 kg) of either sex that had been fed a standard diet of meat and chow described elsewhere (2, 3) . The animals were housed in a facility that met the guidelines of the American Association for the Accreditation of Laboratory Animal Care, and the protocols were approved by the Vanderbilt University Medical Center Animal Care Committee.
A laparotomy was performed 16-18 days before each experiment to implant catheters and ultrasonic (Transonic Systems, Ithaca, NY) flow probes into or around appropriate blood vessels, as described elsewhere (2, 3) . Each dog was used for only one experiment. All dogs studied had 1) a leukocyte count Ͻ18,000/mm 3 , 2) a hematocrit Ͼ35%, 3) a good appetite, and 4) normal stools.
The experiment consisted of a 100-min tracer equilibration and hormone adjustment period (Ϫ140 to Ϫ40 min), a 40-min basal period (Ϫ40 to 0 min), and two 90-min test periods (0-90 and 90-180 min) in groups 1 and 2, plus a 60-min third test period in groups 3 and 4 ( Fig. 1) . In all studies, a priming dose of purified [3- 3 H]glucose (42 Ci) was given at Ϫ140 min, followed by a constant infusion of [3- 3 H]glucose (0.35 Ci/min), [U-
14 C]alanine (0.35 Ci/min), and indocyanine
). An infusion of somatostatin (0.8 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was started at Ϫ130 min to inhibit endogenous insulin and glucagon secretion. Concurrently, intraportal replacement infusions of insulin (300 U ⅐ kg Ϫ1 ⅐ min
Ϫ1
) and glucagon (0.65 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) were started. The plasma glucose level was monitored every 5 min, and euglycemia was maintained by adjusting the rate of insulin infusion. The final alteration in the insulin infusion rate was made Ն30 min before the start of the basal period, and the rate of insulin infusion (mean of 242 U ⅐ kg Ϫ1 ⅐ min Ϫ1 ) remained unchanged thereafter. The study included four groups. In the first group [␣-blockade ϩ NE (␣-bloϩNE); n ϭ 4], phentolamine (2 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) in a solution of 0.07% ascorbic acid was infused during both test periods via the splenic and jejunal vein catheters. NE (50 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ) in 0.07% ascorbic acid was then infused during the second test period via the same catheters. In the second protocol (␣ 1 -bloϩNE; n ϭ 4), prazosin (4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was infused into the splenic and jejunal catheters during all test periods, and NE (50 and 100 ng ⅐ kg Ϫ1 ⅐ min
) was infused through the same catheters during test periods 2 and 3, respectively. In the third protocol (␤-bloϩEPI; n ϭ 4), propranolol (1 g ⅐ kg Ϫ1 ⅐ min
) and EPI (8 ng ⅐ kg Ϫ1 ⅐ min
) were infused in place of phentolamine and NE, respectively. In the fourth protocol (␤ 2 -bloϩEPI; n ϭ 4), butoxamine (40
) was infused into the splenic and jejunal catheters during all test periods, and EPI (8 and 40 ng ⅐ kg Ϫ1 ⅐ min
) was infused through the same catheters during the second and third test periods, respectively. The infusion rates of EPI and NE used in test period 2 of the present study were the same as those used in our previous studies (2, 5) , in which EPI and NE alone had significant stimulatory effects on hepatic glucose production through an effect on glycogenolysis. The infusion rates of EPI and NE used in test period 3 of the present study were the same as those used in our previous study (3) , in which the plasma levels of the catecholamines were increased to the extent seen in extremely stressful situations (i.e., severe hypoglycemia, exhaustive exercise, or hemorrhagic shock). The doses of phentolamine and propranolol infused in the current study were the same as those used in our previous study (3) , in which the two together completely blocked the hepatic glycogenolytic effect of high levels of NE and EPI. The doses of Fig. 1 . Protocol. EPI, epinephrine; NE, norepinephrine; Po, portal.
prazosin and butoxamine were chosen from a dose-response study of the effect of the blockers on the actions of NE and EPI, respectively (data not shown). Any direct effects of the adrenergic blockers were presumed not to change between the adrenergic-blockade-alone period and the blockade-pluscatecholamine infusion period.
Blood pressure and heart rate were measured using methods described elsewhere (2, 3 14 C]glucose, blood lactate, glycerol, ␤-hydroxybutyrate (BOHB), alanine, glutamine, glutamate, glycine, serine, threonine, and plasma FFA were determined with previously described methods (2, 3) . The levels of insulin, glucagon, cortisol, EPI, and NE were also determined as described elsewhere (2, 3) .
Doppler flow probes and indocyanine green dye (ICG) were used to estimate total hepatic blood flow (2, 3). The hepatic blood flow did not change significantly in response to any treatment throughout the study. Because in our studies hepatic blood flows measured by the Doppler method were more stable than those determined by the ICG method, and they did not require an assumption as to the relative contribution of the hepatic artery and portal vein, the data in the figures and tables are those calculated with Doppler-measured flows. The net hepatic balance and fractional extraction of blood glucose, lactate, glycerol, BOHB, alanine, other gluconeogenic amino acids, and plasma FFA were calculated with the use of arteriovenous difference methods described elsewhere (2, 3) . Hepatic sinusoidal plasma NE and EPI levels were calculated by means of an equation described previously (2, 5) . It should be noted that, to the extent that there was hepatic glucose uptake (HGU), total hepatic glucose release [net hepatic glucose output (NHGO) ϩ HGU] would be slightly higher (Ϸ0.2 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 ) than NHGO (2, 19) . Total glucose production (R a ) and utilization (R d ) were determined by use of both one-and two-compartment models, as previously described (2, 3). The results were similar regardless of which approach was employed, because the deviations from steady state were minimal. The R a and R d data shown in the figures and tables are those calculated with the two-compartment method. It should also be noted, because the kidneys produce a small amount of glucose, that the rate of endogenous glucose production determined by the tracer method slightly (Ϸ0.3 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 ) overestimates total hepatic glucose release (18) . This overestimate, however, should be equal in the four groups and would not be expected to change appreciably during the test periods in any group.
Gluconeogenic efficiency was assessed with a double isotope technique described elsewhere (2, 3) . Because the conversion of [ 14 C]alanine to [ 14 C]glucose by the kidney is minimal (15), [ 14 C]glucose production in our study was almost exclusively attributable to the liver. Maximal and minimal rates of gluconeogenesis from circulating gluconeogenic precursors were calculated by use of methods described previously (2, 3) .
Statistical analysis. All statistical comparisons were made with repeated-measures ANOVA with post hoc analysis by use of univariate F tests or the paired Student's t-test where appropriate. Statistical significance was accepted at P Ͻ 0.05. Data are expressed as means Ϯ SE.
RESULTS
Hormone levels. The arterial and portal plasma levels of insulin and glucagon remained at basal values in all groups throughout the study (Fig. 2) . Similarly, the arterial plasma cortisol levels did not change significantly (data not shown). The arterial, portal, and hepatic sinusoidal plasma levels of NE and EPI remained unchanged during the basal and first test periods in all protocols (Fig. 3, 4 , and Table 1 ). During the second test period of the ␣-bloϩNE group, the arterial, portal, and hepatic sinusoidal plasma levels of NE increased from 154 Ϯ 63 to 300 Ϯ 51, 137 Ϯ 31 to 3,351 Ϯ 338, and 136 Ϯ 14 to 2,868 Ϯ 275 pg/ml (P Ͻ 0.05 vs. basal for the portal and sinusoidal levels, Fig. 3 ), respectively. During the second and third test periods of the ␣ 1 -bloϩNE group, the plasma levels of NE increased from 227 Ϯ 42 to 320 Ϯ 40 and 404 Ϯ 58 pg/ml in the artery, 218 Ϯ 76 to 3,765 Ϯ 371 and 7,422 Ϯ 926 pg/ml in the portal vein, and 215 Ϯ 57 to 2,875 Ϯ 283 and 5,721 Ϯ 739 pg/ml in the hepatic sinusoid, respectively (P Ͻ 0.05 vs. basal for the portal and sinusoidal levels, Fig. 3 ).
During the second test period of the ␤-bloϩEPI group, the arterial, portal, and hepatic sinusoidal plasma levels of EPI increased from 53 Ϯ 9 to 66 Ϯ 11, 29 Ϯ 9 to 746 Ϯ 68, and 32 Ϯ 8 to 668 Ϯ 60 pg/ml (P Ͻ 0.05 vs. basal for the portal and sinusoidal levels; Fig.  4 ), respectively. During the second and third test peri- ods of the ␤ 2 -bloϩEPI group, the plasma levels of EPI increased from 104 Ϯ 36 to 94 Ϯ 23 and 117 Ϯ 50 pg/ml in the artery, 51 Ϯ 10 to 633 Ϯ 110 and 3,221 Ϯ 345 pg/ml in the portal vein, and 68 Ϯ 11 to 508 Ϯ 80 and 2,514 Ϯ 322 pg/ml in the hepatic sinusoid, respectively (P Ͻ 0.05 vs. basal for the portal and sinusoidal levels; Fig. 4) .
Hepatic blood flow, arterial blood pressure, and heart rate. Neither hepatic blood flow, mean arterial blood pressure, nor heart rate changed in any protocol (Table  2) .
Glucose levels and kinetics. The arterial blood glucose level did not change significantly in the ␣-bloϩNE, ␣ 1 -bloϩNE, or ␤ 2 -bloϩEPI groups throughout the study (Fig. 5, A and B) . NHGO did not change in response to either form of ␣-adrenergic blockade (Fig.  5A) . Similarly, ␣-adrenergic blockade prevented the increase in NHGO and tracer-determined glucose production that normally results from NE infusion.
Portal infusion of the ␤-blocker propranolol increased the arterial blood glucose level from 83 Ϯ 4 to 114 Ϯ 8 by the end of the first test period (P Ͻ 0.05; Fig.   5B ). This was the result of an increase in NHGO from 2.0 Ϯ 0.5 to 2.
, which occurred within 30 min of blocker infusion. In the presence of ␤-blockade, portal EPI failed to increase the arterial glucose level or NHGO (Fig. 5B) . Portal infusion of the ␤ 2 -blocker butoxamine did not change the arterial blood glucose level or NHGO (Fig. 5B) . In the presence of the ␤ 2 -blocker, neither portal EPI infusion failed to increase the arterial glucose level or NHGO significantly (Fig. 5B) . The glucose production data obtained by the tracer method confirmed a small stimulatory effect of propranolol (Fig. 5, A and B) .
Tracer-determined R d did not change significantly during ␣-or ␣ 1 -blockade (P Ͻ 0.05) and was not affected by portal NE infusion (Table 3) . R d did not change significantly during ␤-blockade but increased slightly during the portal EPI infusion in the presence of propranolol (Table 3 ; P Ͻ 0.05). R d did not change significantly in the ␤ 2 -bloϩEPI group (Table 3) . Glu- cose clearance did not change significantly during ␣-or ␣ 1 -blockade but decreased slightly in response to highdose portal NE infusion (Table 3) . Glucose clearance did not change significantly in the ␤-bloϩEPI and ␤ 2 -bloϩEPI groups (Table 3) .
Blood levels and net hepatic balance of lactate. Neither the arterial level of lactate nor the net hepatic lactate balance changed significantly in the ␣-bloϩNE and ␣ 1 -bloϩNE groups (Fig. 6A) . The arterial lactate level increased from 515 Ϯ 108 to 677 Ϯ 189 and to 846 Ϯ 262 mol/l (P Ͻ 0.05) during the first and second test periods, respectively, in the ␤-bloϩEPI protocol (Fig. 6B) . Net hepatic lactate balance switched from net uptake to net output (Ϫ1.4 Ϯ 1.5 to 4.5 Ϯ 1.8 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 , P Ͻ 0.05) in response to ␤-blockade and remained in output during EPI infusion. Neither the arterial level of lactate nor the net hepatic lactate balance changed significantly in the ␤ 2 bloϩEPI group (Fig. 6B) .
Glycerol, FFA, BOHB, and alanine. Neither the arterial levels nor the net hepatic balances of glycerol changed significantly in the ␣-bloϩNE, ␣ 1 -bloϩNE, and ␤-bloϩEPI groups. The arterial level and net hepatic balance of glycerol decreased slightly in the ␤ 2 -bloϩEPI group during high-dose portal EPI infusion. Neither the arterial plasma levels nor the net hepatic balances of FFA changed significantly in the ␣-bloϩNE, ␣ 1 -bloϩNE, and ␤-bloϩEPI groups throughout the study. The arterial plasma level of FFA decreased gradually from 749 Ϯ 93 to 440 Ϯ 90, and to 320 Ϯ 68 mol/l (both P Ͻ 0.05), and net hepatic uptake decreased from 2.3 Ϯ 0.8 to 0.8 Ϯ 0.5, and to 0.9 Ϯ 0.4 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 (both P Ͻ 0.05), respectively, during the second and third test periods in the ␤ 2 -bloϩEPI group. Neither the arterial levels nor the net hepatic balances of BOHB changed significantly in the ␣-bloϩNE, ␣ 1 -bloϩNE, and ␤-bloϩEPI groups throughout the study. The arterial level and net hepatic output of BOHB decreased gradually from 25 Ϯ 4 to 17 Ϯ 3 and to 16 Ϯ 2 mol/l (both P Ͻ 0.05), as well as from 0.7 Ϯ 0.1 to 0.4 Ϯ 0.1 and to 0.4 Ϯ 0.1 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 (both P Ͻ 0.05), respectively, during the second and third test periods in the ␤ 2 -bloϩEPI group.
The blood level and net hepatic balance of alanine did not change significantly in the ␣-bloϩNE and ␣ 1 -bloϩNE groups (Table 4) . The blood level (283 Ϯ 21 to 399 Ϯ 62 mol/l, P Ͻ 0.05) and net hepatic balance 
Data are means Ϯ SE. EPI, epinephrine; NE, norepinephrine; ad blo, adrenergic blockade; CATS, catecholamines. The data in basal period were calculated based on the samples taken at Ϫ40 and 0 min. * P Ͻ 0.05 vs. corresponding basal period. (Ϫ1.6 Ϯ 0.4 to Ϫ2.6 Ϯ 0.8 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 , P Ͻ 0.05) of alanine increased slightly in the ␤ bloϩEPI group during the portal EPI infusion. The blood level did not change significantly, and the net hepatic balance of alanine increased slightly in the ␤ 2 -bloϩEPI group from Ϫ2.0 Ϯ 0.2 to Ϫ3.8 Ϯ 1.0 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 during the high dose portal EPI infusion.
Gluconeogenic amino acids. The arterial levels and net hepatic balances of glutamate, glutamine, glycine, serine, and threonine did not change significantly in response to any treatment (Table 5) .
Hepatic gluconeogenic and glycogenolytic rates. The gluconeogenic rate did not change significantly in response to any treatment (Fig. 7, A and B) . Because no significant change was seen in gluconeogenic rate, the increase in NHGO observed in response to ␤-blocker infusion alone must have resulted from an increase in hepatic glycogenolysis (1.8 Ϯ 0.3 to 2.8 Ϯ 0.3 mg ⅐ kg Ϫ1 ⅐ min
Ϫ1
; P Ͻ 0.05; Fig. 7B ). Because neither NHGO nor gluconeogenesis changed significantly in response to NE infusion, it is clear that in the presence of ␣-or ␣ 1 -blockade, NE was unable to increase hepatic glycogenolysis significantly (Fig. 7, A and B and Fig. 8 ). Likewise, in the presence of ␤-or ␤ 2 -blockade, EPI was unable to increase hepatic glycogenolysis significantly (Fig. 7, A and B and Fig. 8) . 
Data are means Ϯ SE. TDGU, tracer-determined glucose utilization; TDCL, tracer-determined glucose clearance. The data in basal period were calculated based on the samples taken at Ϫ40 and 0 min. * P Ͻ 0.05 vs. corresponding basal period.
DISCUSSION
The aim of the present study was to determine whether epinephrine and norepinephrine exert their actions on hepatic glucose production in the conscious dog through different adrenergic receptor subtypes.
The arterial and portal levels of insulin and glucagon were clamped at basal values in all groups (Fig. 2) , thereby eliminating any effect of the catecholamines on the pancreas. By bringing about a selective increase in hepatic sinusoidal norepinephrine or epinephrine, we Table 5 . Arterial blood levels and net hepatic balances of glutamate, glutamine, glycine, serine, and threonine during the basal, portal blockade, and portal catecholamine ϩ blockade periods of the ␣-adrenergic blocker ϩ norepinephrine and ␤-adrenergic blocker ϩ epinephrine groups in the presence of a pancreatic clamp in conscious 18-h-fasted dogs
were also able to eliminate the peripheral (muscle and fat) effects of the catecholamines. As a result, there were no significant changes in the blood metabolite levels or any cardiovascular parameters throughout the study (Figs. 6 and 7, Tables 2 and 4) . Similarly, by infusing all adrenergic blockers intraportally, we were able to eliminate the effects of these blockers on the cardiovascular system, because most of them were metabolized by the liver through a first pass effect ( Table  2) . We were thus able to address directly the effect of the catecholamines on the liver per se. Our results showed that the direct effect of norepinephrine on hepatic glucose production was almost completely abolished by ␣-(phentolamine) or ␣ 1 -(prazosin) blockers. Likewise, the direct effect of epinephrine on hepatic glucose production was markedly inhibited by ␤-(propranolol) or ␤ 2 -(butoxamine) blockers. In one of our previous studies using the pancreatic clamp to fix insulin and glucagon at basal levels (5), the same rate of portal norepinephrine infusion as the one used in the present study increased NHGO from 1.9 Ϯ 0.2 to 3.5 Ϯ 0.4 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 (Fig. 8) . It also increased the arterial blood glucose level from 79 Ϯ 5 to 89 Ϯ 6 mg/dl within 30 min. In a control study (5) , that degree of hyperglycemia alone decreased NHGO from 2.1 Ϯ 0.2 to 1.
, so the net effect of norepinephrine on hepatic glucose production was a rise of 1.9 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 . In the current study, in the presence of ␣-or ␣ 1 -adrenergic blockers, a physiological rise in hepatic sinusoidal norepinephrine had no significant effect on NHGO (1.6 Ϯ 0.5 to 1.9 Ϯ 0.7 or 1.6 Ϯ 0.1 to 1.6 Ϯ 0.2 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 over the first 30 min; Fig. 8 ). Furthermore, in the presence of an ␣ 1 -adrenergic blocker, even high sinusoidal plasma norepinephrine levels corresponding to those seen in the synaptic clefts in extremely stressful conditions (Ϸ5,700 pg/ml) failed to increase NHGO significantly (1.7 Ϯ 0.3 to 2.0 Ϯ 0.3 mg ⅐ kg Ϫ1 ⅐ min
Ϫ1
; Fig. 8 ). The results obtained with tracer-determined glucose production paralleled those seen with NHGO. Because our earlier study (5) was performed recently using the same methodology, similar insulin (mean of 245
), and the same glucagon infusion rates, the usual caveats regarding the use of historical data for comparison should not apply. Taken together, the data from our current and earlier studies (5) indicate that the direct effect of norepinephrine on hepatic glucose production is markedly inhibited by ␣-adrenergic blockade and, furthermore, that the effects of the catecholamine are predominantly attributable to ␣ 1 -receptors. In our previous study (5) , the direct effect of norepinephrine on hepatic glucose production was attributable to its effect on hepatic glycogenolysis. Because no significant changes were seen in any gluconeogenic parameter or in NHGO in the current study, one can conclude that the effect of norepinephrine on glycogenolysis was predominantly mediated by ␣ 1 -adrenergic receptors.
Garceau et al. (11) reported that, in the anesthetized dog, the increase in hepatic venous glucose concentration caused by hepatic arterial norepinephrine injection was partially inhibited by either phentolamine or propranolol delivered peripherally. In a human study, Meguid et al. (17) showed that in the absence of a pancreatic clamp, the norepinephrine-induced rise in blood glucose concentration was blocked by 60% when phentolamine was infused. Interpretation of the data from those studies is complicated by the fact that effects of norepinephrine on the pancreas and/or muscle and adipose tissues, as well as on the cardiovascular system and liver, were all present. It has been shown in vitro (6, 12) that norepinephrine has very low affinity for ␤ 2 -receptors (7% that of epinephrine) and that it is this ␤-subtype that predominates in canine liver (14, 17) . This is consistent with our data in which, in the presence of the ␣ 1 -blocker, a slight glycemic (15-20%) effect (Fig. 8 ) was seen only in response to extremely high norepinephrine infusion (test period 3). This may also explain the failure of others to completely block the effects of norepinephrine. Likewise, in vitro work has shown that norepinephrine has a high affinity for ␣ 1 -receptors, and it is this ␣-adrenergic receptor subtype that is found in the canine liver (6, 12, 14) . Thus these in vitro data are in line with our findings and suggest that, in the dog, norepinephrine stimulates hepatic glucose production predominantly by interaction with ␣ 1 -receptors. In another of our previous studies using the pancreatic clamp (2), portal epinephrine infusion at the same rate as in the present study increased NHGO from 2.1 Ϯ 0.3 to 3.7 Ϯ 0.5 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 (Fig. 8) and arterial blood glucose level from 76 Ϯ 2 to 92 Ϯ 3 mg/dl within 30 min. In the control protocol (2) , that degree of hyperglycemia alone decreased NHGO from 2.1 Ϯ 0.2 to 1.4 Ϯ 0.3 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 , so the net effect of epinephrine on hepatic glucose production was an increase of 2.3 mg ⅐ kg Ϫ1 ⅐ min
. In the present study, the effect of the same rise in hepatic sinusoidal epinephrine on NHGO was completely inhibited by portal ␤-or ␤ 2 -adrenergic blockers (2.4 Ϯ 0.9 to 2.2 Ϯ 0.9 or 1.2 Ϯ 0.1 to 1.4 Ϯ 0.2 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 over the first 30 min; Fig. 8 ). Once again, the similarity of our earlier study (2) to the current one and its recent date should allow direct comparison between the two groups. In that study, the direct effect of epinephrine on hepatic glucose production was solely attributable to its effect on hepatic glycogenolysis. Because no significant changes were seen in any gluconeogenic parameter or in NHGO in the current study, one can conclude that the effects of epinephrine on glycogenolysis must be inhibited by ␤-adrenergic blockade.
It should be noted that, in the presence of the ␤ 2 -adrenergic blocker butoxamine, a sinusoidal plasma epinephrine level seen only during extreme stress (Ϸ2,500 pg/ml) increased both NHGO and tracer-determined glucose production by only 0.6 mg ⅐ kg Ϫ1 ⅐ min
over the first 30 min [Ϸ75% inhibition of the response expected based on our earlier data (3)]. There are two possible explanations for the incomplete blockade. First, because the effect of this high level of plasma epinephrine on glucose production was inhibited only 15% by a low-dose butoxamine infusion (4 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ; data not shown), it is possible that the dose of butoxamine (40 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) used in the present study was not high enough to completely abolish the effect of the high level of epinephrine on ␤ 2 -adrenergic receptors. Second, it could be that the effect was attributable to a small ␣-adrenergic action of the catecholamine on hepatic glucose production.
In an earlier study, Steiner et al. (25) showed that preincubation of canine hepatocytes with propranolol (200 nmol/l) caused a 77% inhibition of the glucose output caused by epinephrine. Phentolamine (200 nmol/l), on the other hand, caused a 27% inhibition of the glucose output caused by epinephrine. This suggested that the glycogenolytic effect of epinephrine on the canine hepatocyte is mediated primarily by a ␤-adrenergic mechanism but with a small ␣-component. Rizza et al. (20) reported that, in the absence of a pancreatic hormone clamp, epinephrine can stimulate glucose production in humans via both ␣-and ␤-adrenergic mechanisms. Because both insulin and glucagon increased in their study, it was not possible to determine which adrenergic mechanism was involved in the direct effect of epinephrine on hepatic glucose production.
As noted above, our results suggest that epinephrine exerts little of its effects through ␣-stimulation. In agreement with our data, Deibert and DeFronzo (9) reported that, in the presence of a euglycemic-hyperinsulinemic clamp, all of the effects of epinephrine on glucose production in the human could be accounted for by a ␤-adrenergic mechanism. Similarly, Best et al. (1) , in another human study, showed a lack of a direct ␣-adrenergic effect of epinephrine on glucose production in the presence of a pancreatic clamp. Likewise, Rizza et al. (20) reported that, in the presence of pancreatic hormone clamp in the human, peripherally delivered phentolamine failed to alter the effects of peripherally delivered epinephrine on glucose production. On the other hand, peripherally delivered propranolol (␤-adrenergic blocker) inhibited the effects of epinephrine by 80%. As in our study, the failure to completely inhibit the effect of epinephrine on hepatic glucose production may have resulted from incomplete blockade or a small ␣-component (20) . Taking all of the findings together, one can conclude that the effect of epinephrine on NHGO in the conscious dog is predominantly mediated by ␤ 2 -adrenergic receptors.
Our previous studies (3, 4) showed that combined ␣-ϩ ␤-adrenergic blockade per se increased arterial glucose (77 Ϯ 3 to 92 Ϯ 7 mg/dl), NHGO (2.0 Ϯ 0.2 to 3.3 Ϯ 0.3 mg ⅐ kg Ϫ1 ⅐ min
), and net hepatic lactate output (2.8 Ϯ 2.7 to 9.1 Ϯ 4.8 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ). In the current study, ␤-adrenergic blockade with propranolol alone increased arterial glucose (86 Ϯ 4 to 114 Ϯ 12 mg/dl), as well as NHGO (1.7 Ϯ 0.5 to 2.5 Ϯ 1.0 mg ⅐ kg Ϫ1 ⅐ min
), and switched the liver from net lactate uptake to output (Ϫ2.4 Ϯ 2.6 to 3.7 Ϯ 2.2 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ). No such change was seen during the portal infusion of the ␣-adrenergic blockers or the ␤ 2 -blocker. The present data thus indicate that the effects of the combined ␣-ϩ ␤-adrenergic blockade seen in our previous study (3, 4) were attributable to the ␤-adrenergic blocker propranolol. Also, because no such change was seen during the portal infusion of the ␤ 2 -adrenergic blocker butoxamine in the present study, the effect must be attributable to propranolol itself or to ␤ 1 -stimulation and not to ␤ 2 -adrenergic receptor stimulation. In agreement with our data, Shaw and Wolfe (24) reported that propranolol alone increased glucose production either in the presence or in the absence of a pancreatic hormone clamp in conscious dogs. The explanation for the effect of propranolol on hepatic glucose production is not clear. One possibility is that propranolol may have an intrinsic (partial agonist) effect on ␤-adrenergic receptors and thereby increase glucose production. Another is that propranolol may inhibit glucose oxidation and energy expenditure (7, 23, 24) and thus indirectly increase hepatic glucose release. Regardless, the explanation for this interesting finding remains to be elucidated.
In conclusion, 1) the direct effect of norepinephrine on hepatic glucose production (glycogenolysis) is predominantly mediated through ␣ 1 -adrenergic receptors; 2) the direct effect of epinephrine on hepatic glucose production (glycogenolysis) is predominantly mediated through ␤ 2 -adrenergic receptors. 
